anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Bupropion
Trial phase: Phase 4
ATC code: A08AA62 | N06AX12
SMILES: CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Subjects received 150 mg tablet bupropion SR orally once daily for three days followed by twice daily for a total medication treatment of 12 weeks.

Subjects also received behavioral interventions, which included 35-minute counseling sessions at each of the first 2 visits (enrollment and on the quit day) and 10 minutes of smoking cessation counseling at subsequent visits.
Eligibility criteria:
Inclusion Criteria:

smoking at least 10 CPD prior to pregnancy and 5 CPD for the preceding 7 days
13-30 weeks gestation
≥18 years of age
able to speak English or Spanish
intent to carry pregnancy to term
stable residence

Exclusion Criteria:

current illicit drug or alcohol abuse or dependence
twins or other multiple gestation
treatment for psychiatric disorder within the last 6 months
unstable medical problems (eg, hypertension (BP>140/90), preeclampsia, threatened abortion, hyperemesis gravidarum)
known congenital abnormality
seizure disorder
use of psychotropic medication
use of medication known to lower the seizure threshold
anorexia/bulimia
a personal history of closed head trauma with > 30 minutes of loss of consciousness or amnesia or resulting in skull fracture or subdural hematoma/brain contusion
use of any other smoking cessation treatment in the past 30 days
current enrollment in methadone treatment program
prior pregnancy with preeclampsia diagnosis
chronic hypertension (past history or current diagnosis)
Intervention: Bimatoprost
Trial phase: Phase 3
ATC code: S01EE03
SMILES: CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 87
Group description: One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
Eligibility criteria:
Inclusion Criteria:

Have inadequate eyelashes

Exclusion Criteria:

Any disease/infection/abnormality of the eye or area around the eye
Any ocular surgery within 3 months or anticipated need for ocular surgery during the study
Any permanent eyeliner or implants of any kind or anticipated use of false eyelashes
Any semi-permanent eyelash tint, dye, curl or eyelash extension application within 3 months
Use of any over-the-counter eyelash growth product within 6 months or any use of prescription eyelash growth products
Use of treatments which may affect hair growth (eg, minoxidil, chemotherapy) within 6 months
Intervention: Bimatoprost
Trial phase: Phase 3
ATC code: S01EE03
SMILES: CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
Eligibility criteria:
Inclusion Criteria:

Have inadequate eyelashes due to chemotherapy treatment
Treated for solid tumors such as breast or colorectal cancer in early stages where the cancer has not spread outside the primary organ (eg, stage 1, 2 or 3a for breast cancer)
Have completed chemotherapy treatment for at least 4 weeks but not more than 24 weeks and all side effects related to chemotherapy are recovered, improved or maintained, with the exception of hair loss

Exclusion Criteria:

Any disease/infection/abnormality of the eye or area around the eye
Any ocular surgery within 3 months or anticipated need for ocular surgery during the study
Any permanent eyeliner or implants of any kind or anticipated use of false eyelashes
Any semi-permanent eyelash tint, dye, curl or eyelash extension application within 3 months
Use of any over-the-counter eyelash growth product within 6 months or any use of prescription eyelash growth products
Use of treatments which may affect hair growth (eg, minoxidil) within 6 months except for prior chemotherapy
Intervention: SODIUM CHLORIDE
Trial phase: Not Applicable
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 58
Group description: Placebo (Normal saline) injected into bilateral forehead and frown lines areas on Day 1.
Eligibility criteria:
Inclusion Criteria:

Moderate to severe forehead lines

Exclusion Criteria:

Current or previous botulinum toxin treatment of any serotype within one year
Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis
Prior facial cosmetic surgery (e.g. prior periorbital surgery, facial lift, brow lift, eyelid lift or eyebrow surgery)
Facial laser or light treatment, microdermabrasion, or superficial peels within 3 months
Oral retinoid therapy within one year
Intervention: Allopurinol
Trial phase: Phase 4
ATC code: M04AA01 | M04AA51
SMILES: Oc1ncnc2[nH]ncc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1732
Group description: Treatment.

Allopurinol: Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.
Eligibility criteria:
Inclusion Criteria:

Meets the diagnosis of gout according to the American Rheumatism Association (ARA) Criteria for the Classification of Acute Arthritis of Primary Gout.
Not on a urate lowering therapy (ULT) must have an sUA level ≥ 8.0 mg/dL at screening.
If on concomitant ULT must have an sUA level ≥ 6.5 mg/dL at screening.
Must have had at least 2 gout flares in the past year.

Exclusion Criteria:

Consumption of more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz [150 mL] of wine, 12 oz [360 mL] of beer, or 1.5 oz [45 mL] of hard liquor).
History or suspicion of drug abuse.
History of autoimmune disease requiring systemic treatment.
Known or suspected human immunodeficiency virus (HIV), hepatitis C antibody (HCV), or hepatitis B antibody (HBsAg) infection.
History of malignancy within the previous 5 years (with the exception of nonmelanoma skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia or treated in situ Grade 1 cervical cancer).
Myocardial infarction, unstable angina, New York Heart Association (NYHA) class III or IV heart failure, or stroke within the last 12 months.
Uncontrolled hypertension (systolic pressure above 160 mm Hg or diastolic pressure above 95 mm Hg).
Estimated creatinine clearance < 30 mL/min by Cockcroft-Gault formula.
Kidney or other organ transplant.
Active peptic ulcer disease requiring treatment.
History of xanthinuria, active liver disease, or hepatic dysfunction.
If unable to take gout flare prophylaxis of either colchicine or nonsteroidal anti-inflammatory drugs (NSAIDs) due to contraindication (e.g. toxicity, renal function, use of contraindicated medications).
Known hypersensitivity or allergy to allopurinol.
Intervention: Formoterol
Trial phase: Not Applicable
ATC code: R03AC13 | R03AK07 | R03AK08 | R03AK09 | R03AK11 | R03AL05 | R03AL07 | R03AL09 | R03AL10 | R03AL11 | R03CC15
SMILES: COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Arformoterol aerosol solution (15 mcg/2 mL)via nebulizer
Eligibility criteria:
Inclusion Criteria:

male or female patient 60 years of age or older; diagnosis of COPD; current or former smoker; previous or current use of Diskus device; PIFR < 60 l/min using the In-check DIAL against the resistance of the Diskus device; clinically stable.

Exclusion Criteria:

any patient who has a concomitant disease that might interfere with study procedures or evaluation; inability to withhold short-acting and long-acting bronchodilators on the days of testing
Intervention: Salmeterol
Trial phase: Not Applicable
ATC code: R03AC12 | R03AK06 | R03AK12
SMILES: OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Salmeterol dry powder (50 mcg) via Diskus
Eligibility criteria:
Inclusion Criteria:

male or female patient 60 years of age or older; diagnosis of COPD; current or former smoker; previous or current use of Diskus device; PIFR < 60 l/min using the In-check DIAL against the resistance of the Diskus device; clinically stable.

Exclusion Criteria:

any patient who has a concomitant disease that might interfere with study procedures or evaluation; inability to withhold short-acting and long-acting bronchodilators on the days of testing
Intervention: Pregabalin
Trial phase: Phase 3
ATC code: N02BF02 | N03AX16
SMILES: CC(C)C[C@H](CN)CC(=O)O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: pregabalin (lyrica)

lyrica: 150mg of pregabalin/placebo
Eligibility criteria:
Inclusion Criteria:

Women, 18-70 years of age
ASA physical status I to III
Undergoing unilateral modified radical mastectomy or lumpectomy with axillary node dissection

Exclusion Criteria:

Patients unable to cooperate
Have known allergy to pregabalin or morphine
A history of drug or alcohol abuse
History of chronic pain
Daily intake of analgesics or steroids
Impaired kidney function
Intervention: Pregabalin
Trial phase: Phase 3
ATC code: N02BF02 | N03AX16
SMILES: CC(C)C[C@H](CN)CC(=O)O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: placebo

lyrica: 150mg of pregabalin/placebo
Eligibility criteria:
Inclusion Criteria:

Women, 18-70 years of age
ASA physical status I to III
Undergoing unilateral modified radical mastectomy or lumpectomy with axillary node dissection

Exclusion Criteria:

Patients unable to cooperate
Have known allergy to pregabalin or morphine
A history of drug or alcohol abuse
History of chronic pain
Daily intake of analgesics or steroids
Impaired kidney function
Intervention: Dapagliflozin
Trial phase: Phase 3
ATC code: A10BD15 | A10BD21 | A10BD25 | A10BK01
SMILES: CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 109
Group description: Dapagliflozin 10mg once daily plus background combination of metformin and sulfonylurea
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes mellitus
Men or women age ≥ 18 years old
Stable dose combination of metformin and sulfonylurea
HbA1c ≥7.7% and ≤11.0%

Exclusion Criteria:

Type 1 diabetes mellitus or diabetes insipidus
Recent cardiovascular events
Kidney or urological disorders
Hepatic disorders
Intervention: Milnacipran
Trial phase: Not Applicable
ATC code: N06AX17 | N06AX28
SMILES: CCN(CC)C(=O)C1(c2ccccc2)CC1CN
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: Milnacipran: titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then will taper down.
Eligibility criteria:
Inclusion Criteria:

Individuals between the age of 18 and 65
Headache fulfills ICHD-2 criteria for: chronic migraine, or probable medication overuse headache where individual headaches meet criteria for migraine
At least 15 headache days/month and at least 8 migraine or probable migraine days/month for the past 3 months, by patient report (including days of headache relieved with a triptan or related compound).
Age at onset of chronic migraine < 60 years old

Exclusion Criteria:

Pregnancy or attempting conception
Unable to read or write English
Use of Opiates >/= 10 days per month
Subject has failed >/= 4 adequate preventive trials of antidepressant medications due to lack of efficacy; at least one trial included another SNRI.(An adequate preventive trial defined as at least 6 weeks on therapeutic dose [150mg of amitriptyline or nortriptyline or other tricyclic, 150mg of venlafaxine, 60mg of duloxetine])
Subjects on antidepressant medications, including SNRIs who cannot safely withdraw from those medications, in the assessment of the PI. Subjects on other headache preventives (beta blockers, antiepileptic drugs), at stable dose for at least three months, will be allowed to participate.

A. Subjects on other headache preventives may be included in the study if the medication has been at a stable dose for 3 months.

Presence of fibromyalgia or another pain or medical disorder that would make it difficult for patient to distinguish headache-related quality of life from overall health related quality of life.
Uncontrolled or unstable psychiatric disorder (PHQ-9 score or GAD-7 score >15 with sentinel questions >/=4, or in opinion of examiner), or anticipated need for change in psychotropic medications during duration of study period; or suicidality.
Chronic kidney disease, liver disease, or any poorly controlled medical condition
Intervention: Pituitrin
Trial phase: Phase 4
SMILES: NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 152
Group description: 20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).

Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
Eligibility criteria:
Inclusion Criteria:

The inclusion criteria for our study include all women who are candidates for a laparoscopic or robotic-assisted laparoscopic myomectomy and are willing to accept randomization.
The exclusion criteria: for our study include: suspected malignancy or contraindication to morcellation of uterine tissue, history of adverse reaction or allergy to vasopressin, and active cardiovascular or pulmonary disease that would indicate a contradiction to use of vasopressin.
Intervention: Pituitrin
Trial phase: Phase 4
SMILES: NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 152
Group description: 20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).

Vasopressin: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
Eligibility criteria:
Inclusion Criteria:

The inclusion criteria for our study include all women who are candidates for a laparoscopic or robotic-assisted laparoscopic myomectomy and are willing to accept randomization.
The exclusion criteria: for our study include: suspected malignancy or contraindication to morcellation of uterine tissue, history of adverse reaction or allergy to vasopressin, and active cardiovascular or pulmonary disease that would indicate a contradiction to use of vasopressin.
Intervention: ANGIOTENSIN II
Trial phase: Phase 1
ATC code: C01CX09
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: The angiotensin arm will receive angiotensin II acetate at an initial dose of 20ng/kg/min, titratable during the study (6 hours) for MAP goals as outlined in the protocol.
Eligibility criteria:
Inclusion Criteria:

High-output shock
Cardiovascular SOFA score of > 4
Cardiac Index > 2.4 liters/min/BSA 1.73m2
Indwelling arterial line already present as part of standard care
Age > 21 years of age
Signed consent form
Use of indwelling urinary catheter as standard care expected at least for 12 hours during the study interventions

Exclusion Criteria:

Patients with acute coronary syndrome
Patients with a known history of vasospasm
Patients with a history of asthma
Patients currently experiencing bronchospasm
Patients with active bleeding with an anticipated need for > 4 units of PRBC or Hemoglobin < 7g/dL or any other condition that would contraindicate drawing serial blood samples
Intervention: ANGIOTENSIN II
Trial phase: Phase 1
ATC code: C01CX09
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Control patients will receive placebo intravenously equal in duration, color and volume to the intervention arm's angiotensin II.
Eligibility criteria:
Inclusion Criteria:

High-output shock
Cardiovascular SOFA score of > 4
Cardiac Index > 2.4 liters/min/BSA 1.73m2
Indwelling arterial line already present as part of standard care
Age > 21 years of age
Signed consent form
Use of indwelling urinary catheter as standard care expected at least for 12 hours during the study interventions

Exclusion Criteria:

Patients with acute coronary syndrome
Patients with a known history of vasospasm
Patients with a history of asthma
Patients currently experiencing bronchospasm
Patients with active bleeding with an anticipated need for > 4 units of PRBC or Hemoglobin < 7g/dL or any other condition that would contraindicate drawing serial blood samples
Intervention: Lidocaine
Trial phase: Phase 2
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Child | Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 240
Group description: Topical Lidocaine 4% Cream was applied prior to intravenous cannulation.
Eligibility criteria:
Inclusion Criteria:

Subject is aged 4 to 18 years of age
Subjects will be having a peripheral IV line placed at the discretion of the treating physician for usual care of presenting complaints.
Physician in charge of the subject is willing to wait the 30 minutes needed for the study preparation
Subject/caregiver understands English
Parent or legal guardian has signed Institutional Review Board (IRB) approved informed consent and subject (if age 7 years or older) has given assent

Exclusion Criteria:

Subject is critically ill with a triage category of 1
Subject has a condition that precludes the use of the self-report pain scale
Subject has an abrasion, infection or break in skin in the area where Buzzy® would be placed
Nerve damage is present in the extremity for planned IV placement
Intervention: Acetylcysteine
Trial phase: Not Applicable
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 13
Group description: Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks. Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.

N-acetylcysteine: 600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes

Exclusion Criteria:

Pregnant or lactating females
Uncontrolled diabetes mellitus with severe hyperglycemia (hemoglobin A1C ≥ 9%)
Patients with diabetes mellitus who are taking insulin or glucose-lowering agents other than metformin
Chronic oral or parenteral corticosteroid treatment (>7 consecutive days of treatment) within 8 weeks prior to screening
Use of human immunodeficiency virus (HIV) protease inhibitors or niacin
Chronic inflammatory diseases or use of anti-inflammatory drugs.
Thyroid abnormalities (thyroid-stimulating hormone [TSH] <0.5 or >5 µU/ml)
Creatinine >1.5 in men and >1.3 mg/dl in women
History of dysphagia, gastroparesis, gastric ulcer, malabsorption, swallowing disorders or intestinal motility disorder
Gastroesophageal reflux disease (heartburn) requiring treatment.
Active cancer
Clinical hepatic disease or alanine aminotransferase (ALT) greater than ≥ 1.5 times upper limit of normal within 60 days preceding the first dose of the study drug
Weight loss of >5% body weight within the last 6 months, or starting an intensive exercise program within 4 weeks of study initiation
Smoke or use tobacco
Excessive alcohol consumption (>2 drinks a day)
Use of any investigational drug in the last 30 days
Anemia (hematocrit <33%), donation of one unit (500 ml) or more of blood, significant blood loss equaling at least one unit of blood within the past 2 weeks or a blood transfusion within 8 weeks prior to screening
Employment by the research center
Intervention: Bupivacaine
Trial phase: Phase 2 | Phase 3
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 39
Group description: The caudal epidural block will be delivered with 1.5ml/kg of 0.25% Bupivacaine up to a maximum of 30 mL.

Bupivacaine: 0.25% or 0.5%
Eligibility criteria:
Inclusion Criteria:

ASA physical status I or II
Weight less than or equal to 20 kg
Presenting for repair of umbilical hernia

Exclusion Criteria:

ASA physical status > II
Weight greater than 20 kg
Co-morbid diseases (cardiac, pulmonary, neurological disease)
Patients having concomitant procedures (circumcision, orchiopexy, etc.)
Intervention: Bupivacaine
Trial phase: Phase 2 | Phase 3
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 39
Group description: The rectus sheath block will be performed with 0.1ml/kg of 0.25% Bupivacaine on each side at the T9-T10 distribution under ultrasound guidance.

Bupivacaine: 0.25% or 0.5%
Eligibility criteria:
Inclusion Criteria:

ASA physical status I or II
Weight less than or equal to 20 kg
Presenting for repair of umbilical hernia

Exclusion Criteria:

ASA physical status > II
Weight greater than 20 kg
Co-morbid diseases (cardiac, pulmonary, neurological disease)
Patients having concomitant procedures (circumcision, orchiopexy, etc.)
Intervention: Bupivacaine
Trial phase: Phase 2 | Phase 3
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 39
Group description: The surgeon will inject either 0.5% Bupivicaine 0.5ml/kg or 0.25% Bupivicaine 1ml/kg at the surgeon's discretion.

Bupivacaine: 0.25% or 0.5%
Eligibility criteria:
Inclusion Criteria:

ASA physical status I or II
Weight less than or equal to 20 kg
Presenting for repair of umbilical hernia

Exclusion Criteria:

ASA physical status > II
Weight greater than 20 kg
Co-morbid diseases (cardiac, pulmonary, neurological disease)
Patients having concomitant procedures (circumcision, orchiopexy, etc.)